Skip to main content

Rickard Kathleen A.'s Form 4 filing

Verona Pharma plc (VRNA) · filed Feb 3, 2023

Accession no.
0001104659-23-010733
Filed
Feb 3, 2023
Trade date
Jan 20-Feb 2, 2023
Filing delay
14 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $303.0K. It was filed 14 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rickard Kathleen A.CIK 0001836883Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 20, 2023Ordinary SharesMOption exerciseAcquired+105,000$0.00$03,196,024Direct
Feb 1, 2023Ordinary SharesSSaleDisposed−89,960$2.56F3−$230,297.63,106,064Direct
Feb 2, 2023Ordinary SharesSSaleDisposed−28,752$2.53F5−$72,742.563,077,312Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 20, 2023Ordinary SharesMOption exerciseDisposed−105,000$0.00$015,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported represents the sale price of the ADSs divided by eight (8).

Referenced by the price of 1 transaction in Table I.

F5

The price reported represents a weighted average sale price of the ADSs divided by eight (8). These shares were sold in multiple transactions at prices ranging from $2.4738 to $2.6063, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)